• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: OGDEN MANUFACTURING PLANT OPTIFLUX 180NRE DIALYZER FINISHED ASSY. DIALYZER, HIGH PERMEABILITY WITH OR WITHOUT SEALED DIALYSATE SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

OGDEN MANUFACTURING PLANT OPTIFLUX 180NRE DIALYZER FINISHED ASSY. DIALYZER, HIGH PERMEABILITY WITH OR WITHOUT SEALED DIALYSATE SYSTEM Back to Search Results
Catalog Number 0500318E
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Hypersensitivity/Allergic reaction (1907); Rash (2033); Swelling (2091)
Event Date 02/14/2018
Event Type  Injury  
Manufacturer Narrative
A supplemental medwatch report will be submitted upon completion of the investigation.
 
Event Description
A user facility hemodialysis (hd) patient reported during hemodialysis treatment the patient became symptomatic with a rash on his face, back, chest, and arms as well as swelling of the lips while on treatment. The patient's treatment was shortened because of the symptoms. Per rn the patient had been using the fresenius optiflux 180 nr dialyzer at the time of the event. The patient had been receiving dialysis since (b)(6) 2011 and had been using fresenius dialyzers. The patient remained symptomatic for the next few days and went to the emergency room (er) from home on (b)(6) 2018 as a precaution. The patient was given a prescription for prednisone and was also advised to take benadryl. Per rn the patient was not admitted to the hospital and was sent home from the er. Additional follow-up made with the rn on 03/15/2018 revealed the patient was given a prescription (date unknown) for prednisone (dosage and frequency unknown) to take while waiting for the exeltra 170 dialyzer to be delivered. The patient underwent hemodialysis (hd) treatments on (b)(6) 2018 without incident. The rn stated the exeltra 170 dialyzer was available for hd treatment on (b)(6) 2018, and the treatment was completed without incident. The patient's dialysis treatment related medications (i. E. Hectorol) continued to be held.
 
Manufacturer Narrative
Conclusion: there is a temporal relationship between the hd treatment and the fresenius optiflux 180nre dialyzer on (b)(6) 2018 and the reported adverse reports rash and itching which required subsequent treatment with prednisone and benadryl on (b)(6) 2018. While uncommon, hypersensitivities reactions are known to occur with use of optiflux dialyzers. Additionally, hypersensitivity reactions have been known to occur months, even years after use with the same dialyzer model during additional follow-up it was reported the patient was given prednisone prior to hd therapy on 03/09/2018 and 03/12/2018 and was able to complete treatment without complaint(s). Additionally, the patient was changed to a baxter exeltra 170 on (b)(6) 2018 and completed treatment without complaint(s), thus indicating a strong possibility the patient may have experienced a hypersensitivity reaction to the optiflux 180nre dialyzer. However the patient also received iv hectorol 1,000 mcg, prior to the reported event(s) of rash and itching; both of which are documented hypersensitivity reactions to hectorol. Therefore based on the proximity of these two factors, causality cannot fully be determined. A supplemental medwatch report will be submitted upon completion of the investigation.
 
Event Description
Information in the complaint file and records were reviewed by a post market surveillance clinician. On (b)(6) 2018 an registered nurse (rn) stated this patient with end stage renal disease (esrd) on hemodialysis (hd) experienced itching (location unknown) and a rash (severity and location unknown) while receiving hd therapy on (b)(6) 2018. The rn stated the patient had been utilizing an optiflux 180nre dialyzer since 03/04/2011 and has experienced a shortened treatment. A follow-up e-mail was received on (b)(6) 2018 from the rn stated the patient was able to complete treatment on (b)(6) 2018, as the event(s) occurred at the end of the hd treatment. No treatment data was presently available. Reportedly the patient experienced itching and a rash, and eventually went to the emergency room (er) on (b)(6) 2018 (discharge date unknown) as the event ¿continued to bother¿ him. The hospital course and discharge disposition of the patient were unknown. The rn reported the patient received a prescription for prednisone (dosage, duration and frequency unknown) and was told to take benadryl (dosage, duration, and frequency unknown).
 
Manufacturer Narrative
The reported complaint was not confirmed as the complaint device was not returned for manufacturer evaluation. As no lot number was provided for this complaint, a search was performed to obtain all lot numbers with the reported catalog number delivered to the patient¿s dialysis unit in the three months prior to the complaint occurrence date. Twelve lots were found to have been delivered in this time period. A production records review was performed on the reported lots. An investigation of the device history records (dhr) was conducted by the manufacturer. There were two approved temporary deviation notices (dns) reported on two of the lots which were unrelated to the complaint event. There was one approved temporary dn reported on eight of the lots which was unrelated to the complaint event. Additionally, there was one approved temporary dn and one approved nonconformance report (ncr) on two of the lots which were unrelated to the reported event. There was no indication of product nonacceptance, deviation, non-conformance, rework, labeling or process control failure during the manufacturing process which could be associated with the reported event. The lots met all release criteria. A definitive conclusion regarding the complaint incident cannot be reached without physical examination of the actual device. Therefore, the complaint is not confirmed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameOPTIFLUX 180NRE DIALYZER FINISHED ASSY.
Type of DeviceDIALYZER, HIGH PERMEABILITY WITH OR WITHOUT SEALED DIALYSATE SYSTEM
Manufacturer (Section D)
OGDEN MANUFACTURING PLANT
475 west 13th street
ogden UT 84404
MDR Report Key7342771
MDR Text Key102524972
Report Number1713747-2018-00088
Device Sequence Number1
Product Code KDI
Combination Product (y/n)N
PMA/PMN Number
K002761
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Type of Report Initial,Followup,Followup
Report Date 09/04/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/15/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator
Device Catalogue Number0500318E
Was Device Available for Evaluation? No
Was the Report Sent to FDA?
Device Age MO
Event Location No Information
Date Manufacturer Received09/04/2018
Is This a Reprocessed and Reused Single-Use Device? No

Patient Treatment Data
Date Received: 03/15/2018 Patient Sequence Number: 1
Treatment
ASPIRIN; HYDROXYZINE; LEVOTHYROXINE; METAMUCIL; NEPRO CARB STEADY; PREDNISONE; PROTONIX; RENAPLEX; ASPIRIN; HYDROXYZINE; LEVOTHYROXINE; METAMUCIL; NEPRO CARB STEADY; PREDNISONE; PROTONIX; RENAPLEX
-
-